Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology

She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River

Merck completes acquisition of JSR Life Sciences’ chromatography business

Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing

Lupin receives FDA’s tentative approval for Sugammadex injection

Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery

Novartis acquires Excellergy to bolster allergy portfolio

The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments

Otsuka Pharma to acquire Transcend Therapeutics in $1.225 billion deal

Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones

Merck strikes $6.7 billion deal to acquire terns, bolstering cancer pipeline

TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances

New diabetes drug UBT251 shows strong phase 2 results in China

Zealand Pharma launches major US research hub in Cambridge, Massachusetts

The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities

Earendil Labs bags $787m to supercharge AI-driven biologics pipeline

Capital infusion to accelerate Earendil’s R&D platform

Zydus launches affordable Semaglutide in India after patent expiry

Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders